Under each Therapeutic Area, we norm for the following:

The results - Some metrics
Norms
Industry
Numoda
Improved
SUCCESS RATE:
In Phase III Clinical Trials

Phase II = 33%(1)
Phase III = 55%

>90%
>90%

>172%
>64%
ENROLLMENT:
Percent of invalid patients enrolled


7.5% (EDC)-15%(paper)(2) 


<1%

>86%-93%

DATA QUALITY:
Queries/page of patient data

1(3)
<0.4
>60%

SPEED:
Study database start-up
Time needed to database lock
after last patient data

51.5 days(4) 

>65 days(3)
<21 days

Hours
>62%

>30X
(1) Lehman Brothers, 2006 “Late-Stage R&D Productivity: A Lehman Look at European Pharma R&D.”
(2) Dr. Thomas Bart, “Comparison of Electronic Data Capture with Paper Data Collection,” Pharmwatch, 2003.
(3) Kola and Landis, “Can the pharmaceutical industry reduce attrition rates?;” Nature Rev Drug Discovery. 3, 711-715 (2004); Practical Guide to Clinical Data Management, Second Edition, p. 66; INC Research.
(4) Fitzmartin RD, Drug Information Journal 2001; 35:671-679